European Probiotics specialist Probi has acquired a stake in US supplements firm Vital Nutrients, in a deal which will see the companies collaborate on new product development. 

Novartis passed up the chance for further development of Kyorin's mocravimod for autoimmune diseases but newly formed Priothera is evaluating the S1P receptor modulator for acute myeloid leukemia patients undergoing hematopoietic stem cell transplantation.

The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.